Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 211,355,139 papers from all fields of science
Search
Sign In
Create Free Account
enalkiren
Known as:
(Alpha-S)-Alpha-((Alpha-S)-Alpha-(3-Amino-3-Methylbutyramido)-p-Methoxyhydrocinnamamido)-N-((1S,2R,3S)-1-(Cyclohexylmethyl)-2,3-Dihydroxy-5-Methylhexyl)Imidazole-4-Propionamide
, (N-(3-amino-3-methyl-1-oxobutyl)-4-methoxy-L-phenylalanyl)-N-(1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-L-histidinamide
, L-Histidinamide, N-(3-amino-3-methyl-1-oxobutyl)-O-methyl-L-tyrosyl-N-(1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-, (1S-(1R*,2S*,3R*))-
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Narrower (1)
A 64662
Broader (2)
Dipeptides
Protease Inhibitors
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1995
1995
Renal vascular responses to renin inhibition with zankiren in men
N. Fisher
,
Norman H. Hollenberg
Clinical pharmacology and therapy
1995
Corpus ID: 8696291
1995
1995
Intrarenal angiotensin II formation in humans. Evidence from renin inhibition.
N. Fisher
,
D. Allan
,
C. Gaboury
,
N. Hollenberg
HYPERTENSION
1995
Corpus ID: 13027552
Highly Cited
1994
Highly Cited
1994
Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans.
N. Fisher
,
D. Allan
,
+4 authors
N. Hollenberg
HYPERTENSION
1994
Corpus ID: 6131284
We compared the renal vascular responses to angiotensin converting enzyme inhibition and renin inhibition to assess the influence…
Expand
1992
1992
C-terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties.
S. Boyd
,
A. Fung
,
+7 authors
V. Klinghofer
Journal of Medicinal Chemistry
1992
Corpus ID: 32560209
We describe the development of a series of soluble, potent, and bioavailable nonpeptide renin inhibitors. These inhibitors…
Expand
1991
1991
Renal and Endocrine Responses to a Renin Inhibitor, Enalkiren, in Normal Humans
P. Cordero
,
N. Fisher
,
T. Moore
,
R. Gleason
,
G. Williams
,
N. Hollenberg
HYPERTENSION
1991
Corpus ID: 540596
Interpretation of renin-angiotensin blockade with angiotensin converting enzyme inhibitors is potentially confounded by their…
Expand
1990
1990
Synthesis of polypeptides by microwave heating II. Function of polypeptides synthesized during repeated hydration-dehydration cycles
Masahiko Ito
,
N. Handa
,
H. Yanagawa
Journal of Molecular Evolution
1990
Corpus ID: 45975236
SummaryPolypeptides, synthesized from a mixture of amino acid amides by microwave heating during repeated hydration-dehydration…
Expand
1990
1990
Prolonged Duration of Blood Pressure Response to Enalkiren, the Novel Dipeptide Renin Inhibitor, in Essential Hypertension
R. Boger
,
H. Glassman
,
+6 authors
R. Luther
HYPERTENSION
1990
Corpus ID: 487458
The effects of sustained renin inhibition by repeated administration of enalkiren (A- 64662), the novel dipeptide renin inhibitor…
Expand
1990
1990
Effects of renin inhibition in systemic hypertension.
P. W. Anderson
,
Y. Do
,
+4 authors
W. Hsueh
American Journal of Cardiology
1990
Corpus ID: 21524462
Review
1990
Review
1990
Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor.
H. Glassman
,
H. Kleinert
,
R. Boger
,
D. Moyse
,
A. Griffiths
,
R. Luther
Journal of Cardiovascular Pharmacology
1990
Corpus ID: 31383514
Enalkiren (A-64662), a potent, dipeptide renin inhibitor, mimics the transition state of the human renin substrate…
Expand
Highly Cited
1989
Highly Cited
1989
Hemodynamic and Humoral Effects of the New Renin Inhibitor Enalkiren in Normal Humans
A. Delabays
,
Jiirg Nussberger
,
+7 authors
H. Brunner
HYPERTENSION
1989
Corpus ID: 22845782
The effect of the renin inhibitor enalkiren (Abbott- 64662) was evaluated in eight normal volunteer subjects on a standardized…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE